

Amendments to the Claims:

Please amend claims 5, 7-9 and 23; add new claims 24-28, and cancel claims 1, 3-4 and 10-22. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-4. (Canceled)

5. (Currently Amended) An isolated nonapeptide ~~or decapeptide~~ consisting of ~~a peptide having~~ an amino acid sequence selected from the group consisting of ~~the amino acid sequence of~~ SEQ ID NO: 29, 30, ~~33, 34, 40, and 46~~ and SEQ ID NO: 54 ~~or a peptide with cytotoxic T cell inducibility~~, wherein ~~zero~~, one or two amino acids have been substituted ~~or added to the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46~~, wherein the nonapeptide binds to an HLA-A 0201 restricted T cell receptor with high affinity and induces a high CTL response.

6. (Canceled)

7. (Currently Amended) The peptide of claim 5, wherein the second amino acid from the N terminus is leucine or ~~methionine~~ isoleucine.

8. (Currently Amended) The peptide of claim 5 ~~[[or 7]]~~, wherein the C-terminal amino acid is ~~valine~~ or leucine.

9. (Currently Amended) ~~A pharmaceutical composition for treating and/or preventing tumors, wherein the pharmaceutical comprises~~ comprising one or more peptides of claim 5.

10-22. (Canceled)

23. (Previously Presented) The peptide of claim 5, wherein said peptide has an consists of the amino acid sequence as set forth in SEQ ID NO:54.
24. (New) The peptide of claim 5, wherein said peptide consists of the amino acid sequence as set forth in SEQ ID NO: 30.
25. (New) The peptide of claim 5, wherein zero or one amino acids have been substituted.
26. (New) The peptide of claim 25, wherein the second amino acid from the N terminus is substituted.
27. (New) The composition of claim 9, further comprising a pharmaceutically acceptable carrier.
28. (New) The composition of claim 9, further comprising an adjuvant.